Last reviewed · How we verify
Geptanolimab Injection 280mg, q3w — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Geptanolimab Injection 280mg, q3w (Geptanolimab Injection 280mg, q3w) — Genor Biopharma Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Geptanolimab Injection 280mg, q3w TARGET | Geptanolimab Injection 280mg, q3w | Genor Biopharma Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Geptanolimab Injection 280mg, q3w CI watch — RSS
- Geptanolimab Injection 280mg, q3w CI watch — Atom
- Geptanolimab Injection 280mg, q3w CI watch — JSON
- Geptanolimab Injection 280mg, q3w alone — RSS
Cite this brief
Drug Landscape (2026). Geptanolimab Injection 280mg, q3w — Competitive Intelligence Brief. https://druglandscape.com/ci/geptanolimab-injection-280mg-q3w. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab